Abstract
The primary purpose of this chapter is to review current clinical staging information in schizophrenia spectrum disorders. In the last two decades, clinical staging has been integrated into psychiatry. Its major purpose is to categorize the disorder’s progression into distinct phases based on severity, progression, and disease features to better anticipate outcomes as well as choose appropriate therapeutic interventions. There is no clinical unanimity on which staging model is the gold standard, when they are combined, an integrated staging notion emerges. There are four phases in the integrated staging framework of schizophrenia spectrum disorder. The chapter will offer the integrated staging model, which will detail the features, timing, and prevailing manifestations of every stage in chronological order. Suitable therapeutic interventions for the various phases will be described as well. There are several aims to this chapter. This study attempts to educate people about schizophrenia and minimize stigma. There are still a lot of misunderstandings regarding schizophrenia, and it is still a mental health issue that is rarely spoken about. This chapter will create awareness for the readers about schizophrenia and its procession. It will also familiarize readers with different stages of schizophrenia, and challenges encountered in the management of schizophrenic people.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Addington J (2003) The prodromal stage of psychotic illness: observation, detection or intervention? J Psychiatry Neurosci 28:93–97
Agius M, Goh C, Ulhaq S, McGorry P (2010) The staging model in schizophrenia, and its clinical implications. Psychiatr Danub 22:211–220
al-Haddad BJS, Oler E, Armistead B et al (2019) The fetal origins of mental illness. Am J Obstet Gynecol 221:549–562
Andreasen NC, Carpenter WT, Kane JM et al (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441–449
Ashok AH, Baugh J, Yeragani VK (2012) Paul Eugen Bleuler and the origin of the term schizophrenia (SCHIZOPRENIEGRUPPE). Indian J Psychiatry 54:95
Berendsen S, van der Paardt JW, Van HL et al (2020) Staging and profiling for schizophrenia spectrum disorders: inter-rater reliability after a short training course. Prog Neuropsychopharmacol Biol Psychiatry 99
Bromet EJ, Fennig S (1999) Epidemiology and natural history of schizophrenia. Biol Psychiatry 46:871–881
Buehlmann E, Berger GE, Aston J et al (2010) Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. J Psychiatr Res 44:447–453. https://doi.org/10.1016/J.JPSYCHIRES.2009.10.008
Cerveri G, Gesi C, Mencacci C (2019) Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat 15:1525–1535. https://doi.org/10.2147/NDT.S201726
Cornblatt B, Lencz T, Obuchowski M (2002) The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr Res 54:177–186. https://doi.org/10.1016/S0920-9964(01)00365-6
Correll CU, Kishimoto T, Nielsen J, Kane JM (2011) Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther 33:B16–B39. https://doi.org/10.1016/J.CLINTHERA.2011.11.016
Cosci F, Fava GA (2013) Staging of mental disorders: systematic review. Psychother Psychosom 82:20–34. https://doi.org/10.1159/000342243
Costa LG, Massuda R, Pedrini M et al (2014) Functioning in early and late stages of schizophrenia. Trends Psychiatry Psychother 36:209–213. https://doi.org/10.1590/2237-6089-2014-0028
Dienel SJ, Lewis DA (2019) Alterations in cortical interneurons and cognitive function in schizophrenia. Neurobiol Dis 131:104208. https://doi.org/10.1016/J.NBD.2018.06.020
Dombi ZB, Barabássy Á, Sebe B et al (2021) Clinical staging in schizophrenia spectrum disorders. Psychos Phenomenol Psychopathol Pathophysiol. https://doi.org/10.5772/INTECHOPEN.98276
Ebert A, Bär KJ (2010) Emil Kraepelin: a pioneer of scientific understanding of psychiatry and psychopharmacology. Indian J Psychiatry 52:191. https://doi.org/10.4103/0019-5545.64591
Fava GA, Tomba E, Sonino N (2012) Clinimetrics: the science of clinical measurements. Int J Clin Pract 66:11–15. https://doi.org/10.1111/J.1742-1241.2011.02825.X
Folsom DP, Lebowitz BD, Lindamer LA et al (2006) Schizophrenia in late life: emerging issues. Dialogues Clin Neurosci 8:45. https://doi.org/10.31887/DCNS.2006.8.1/DFOLSOM
Fountoulakis KN, Dragioti E, Theofilidis AT et al (2019) Staging of schizophrenia with the use of PANSS: an international multi-center study. Int J Neuropsychopharmacol 22:681. https://doi.org/10.1093/IJNP/PYZ053
Hickie IB, Scott J, McGorry PD (2013) Clinical staging for mental disorders: a new development in diagnostic practice in mental health. Med J Aust 198:461–462. https://doi.org/10.5694/MJA13.10431
Hoffman BF (1982) The stages of schizophrenia and their management. Can Fam Physician 28:2046–2050
Hultman CM, Sparén P, Takei N et al (1999) Prenatal and perinatal risk factors for schizophrenia, affective psychosis, and reactive psychosis of early onset: case-control study. BMJ Br Med J 318:421. https://doi.org/10.1136/BMJ.318.7181.421
Insel TR (2010) Rethinking schizophrenia. Nature 468:187–193. https://doi.org/10.1038/NATURE09552
Iritani S (2013) What happens in the brain of schizophrenia patients?: An investigation from the viewpoint of neuropathology. Nagoya J Med Sci 75:11
Jobe TH, Harrow M (2005) Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry 50:892–900. https://doi.org/10.1177/070674370505001403
Johnson DAW, Freeman H (1973) Drug defaulting by patients on long-acting phenothiazines. Psychol Med 3:115–119. https://doi.org/10.1017/S0033291700046407
Kessler RC, Berglund P, Demler O et al (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593–602. https://doi.org/10.1001/ARCHPSYC.62.6.593
Lee BJ, Kim SW, Kim JJ et al (2020) Defining treatment response, remission, relapse, and recovery in first-episode psychosis: a survey among Korean experts. Psychiatry Investig 17:163–174. https://doi.org/10.30773/PI.2019.0240
Lieberman JA, Perkins D, Belger A et al (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50:884–897. https://doi.org/10.1016/S0006-3223(01)01303-8
Löhrs L, Hasan A (2019) Risk factors for the development of schizophrenia. Fortschr Neurol Psychiatr 87:133–146. https://doi.org/10.1055/A-0836-7839
McGlashan TH (1988) A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull 14:515–542. https://doi.org/10.1093/SCHBUL/14.4.515
McGorry PD, Purcell R, Hickie IB et al (2007) Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust 187:S40–S42. https://doi.org/10.5694/J.1326-5377.2007.TB01335.X
McGorry PD, Nelson B, Goldstone S, Yung AR (2010) Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can J Psychiatry 55:486–497. https://doi.org/10.1177/070674371005500803
McGrath JJ, Susser ES (2009) New directions in the epidemiology of schizophrenia. Med J Aust 190:S7–S9. https://doi.org/10.5694/J.1326-5377.2009.TB02366.X
McGuire P, Selvaraj S, Howes O (2011) Is clinical intervention in the ultra high risk phase effective? Rev Bras Psiquiatr 33 Suppl 2:s161–s174. https://doi.org/10.1590/S1516-44462011000600004
Miller BJ (2008) A review of second-generation antipsychotic discontinuation in first-episode psychosis. J Psychiatr Pract 14:289–300. https://doi.org/10.1097/01.PRA.0000336756.65308.83
Novick D, Montgomery W, Cheng Y et al (2015) Impact of negative symptoms on quality of life in patients with schizophrenia. Value Heal 18:A836–A837. https://doi.org/10.1016/J.JVAL.2015.09.351
Palazzolo J, Brousse G, Favre P, Llorca PM (2005) The information of the schizophrenic patient: actuality. Encephale 31:227–234. https://doi.org/10.1016/S0013-7006(05)82389-9
Patel KR, Cherian J, Gohil K, Atkinson D (2014) Schizophrenia: overview and treatment options. Pharm Ther 39:638
Roberts J, Gracia Canales A, Blanthorn-Hazell S et al (2018) Characterizing the experience of agitation in patients with bipolar disorder and schizophrenia. BMC Psychiatry 18:104. https://doi.org/10.1186/S12888-018-1673-3
Roy A (1982) Suicide in chronic schizophrenia. Br J Psychiatry 141:171–177. https://doi.org/10.1192/BJP.141.2.171
Rund BR (2009) Is schizophrenia a neurodegenerative disorder? Nord J Psychiatry 63:196–201. https://doi.org/10.1080/08039480902767286
Schmidt SJ, Schultze-Lutter F, Schimmelmann BG et al (2015) EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 30:388–404. https://doi.org/10.1016/J.EURPSY.2015.01.013
Schultz SH, North SW, Shields CG (2007) Schizophrenia: a review. Am Fam Physician 75:1821–1829
Sharma AM, Kushner RF (2009) A proposed clinical staging system for obesity. Int J Obes (Lond) 33:289–295. https://doi.org/10.1038/IJO.2009.2
Shepherd M, Watt D, Falloon I, Smeeton N (1989) The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl 15:1–46. https://doi.org/10.1017/S026418010000059X
Singh SP, Cooper JE, Fisher HL et al (2005) Determining the chronology and components of psychosis onset: the Nottingham Onset Schedule (NOS). Schizophr Res 80:117–130. https://doi.org/10.1016/J.SCHRES.2005.04.018
Stilo SA, Murray RM (2019) Non-genetic factors in schizophrenia. Curr Psychiatry Rep 21:100. https://doi.org/10.1007/S11920-019-1091-3
Tandon R, Nasrallah HA, Keshavan MS (2009) Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res 110:1–23. https://doi.org/10.1016/J.SCHRES.2009.03.005
Volavka J, Vevera J (2018) Very long-term outcome of schizophrenia. Int J Clin Pract 72:e13094. https://doi.org/10.1111/IJCP.13094
Wood SJ, Yung AR, McGorry PD, Pantelis C (2011) Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia. Biol Psychiatry 70:619–625. https://doi.org/10.1016/J.BIOPSYCH.2011.05.034
Wright JR (2012) Albert C. Broders’ paradigm shifts involving the prognostication and definition of cancer. Arch Pathol Lab Med 136:1437–1446. https://doi.org/10.5858/ARPA.2011-0567-HP
Wyatt RJ (1991) Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17:325–351. https://doi.org/10.1093/SCHBUL/17.2.325
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Sahito, A.M. et al. (2023). Different Phases of Schizophrenia Patients: From the Psychological Perspective. In: Chatterjee, I. (eds) Cognizance of Schizophrenia:: A Profound Insight into the Psyche. Springer, Singapore. https://doi.org/10.1007/978-981-19-7022-1_12
Download citation
DOI: https://doi.org/10.1007/978-981-19-7022-1_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-7021-4
Online ISBN: 978-981-19-7022-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)